etanercept · Enbrel

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (5)
US
  • Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
  • Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).
Product first approved 1998Outside this platform's coverageFDA label
CA
  • ENBREL is indicated for: • treatment of moderately to severely active rheumatoid arthritis (RA) in adults. Treatment is effective in reducing the signs and symptoms of RA, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function. ENBREL can be initiated in combination with methotrexate (MTX) in adult patients or used alone. • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4 to 17 years who have had an inadequate response to one or more disease-modifying...
Product first approved 2005Health Canada
EU
  • Enbrel: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis (adults and paediatric)
Product first approved 2000EMA
JP
  • Rheumatoid arthritis; Wyeth K.K. and Takeda
healthday.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (63)
Psoriasis
NCT03073200 · Eli Lilly and Company
2017-03-28 – 2021-03-23 · Plaque Psoriasis
What this study did
NCT02701205 · Shanghai Celgen Bio-Pharmaceutical Co.,Ltd
2015-01 – 2017-12 · Plaque Psoriasis, Psoriasis
What this study did
NCT00141921 · Amgen
2005-08-11 – 2017-08-16 · Pediatric Plaque Psoriasis
What this study did
NCT01313221 · Amgen
2011-04 – 2013-05 · Psoriasis
What this study did
NCT01235442 · Amgen
2010-09 – 2011-12 · Psoriasis
What this study did
NCT00482170 · Pfizer
2007-09 – 2009-09 · Psoriasis
What this study did
NCT00121615 · Amgen
started 2004-10 · Inflammation, Psoriasis
What this study did
NCT00333034 · Wyeth is now a wholly owned subsidiary of Pfizer
2006-06 – 2007-05 · Psoriasis
What this study did
NCT00116181 · Rockefeller University
2004-10 – 2007-01 · Psoriasis
What this study did
Psoriatic Arthritis
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT01690299 · Amgen
2012-10-01 – 2016-04-04 · Psoriasis, Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT03414502 · University of Nebraska
2007-12-10 – 2029-03 · Rheumatoid Arthritis
What this study did
NCT02373813 · Amgen
2015-02-20 – 2019-12-06 · Rheumatoid Arthritis
What this study did
NCT03403140 · Gema Biotech S.A.
2016-10-06 – 2018-10-31 · Rheumatoid Arthritis
What this study did
NCT02986139 · Amgen
2016-11-29 – 2017-10-09 · Arthritis, Rheumatoid; Arthritis, Psoriatic
What this study did
NCT03332719 · Gema Biotech S.A.
2016-02 – 2017-09 · Rheumatoid Arthritis
What this study did
NCT02638259 · Sandoz
2015-02-21 – 2017-06-12 · Rheumatoid Arthritis
What this study did
NCT02378506 · Pfizer
2015-04 – 2016-06 · Arthritis, Rheumatoid
What this study did
NCT02164214 · Assistance Publique Hopitaux De Marseille
2011-09 – 2015-09 · Inflammatory Rheumatism, Psoriatic Arthritis, Rheumatoid Arthritis
What this study did
NCT01901185 · Amgen
2013-06-11 – 2013-12-30 · Rheumatoid Arthritis, Psoriatic Arthritis
What this study did
NCT00110903 · Amgen
— · Rheumatoid Arthritis
What this study did
NCT01270997 · Hanwha Chemical
2010-12 – 2012-05 · Rheumatoid Arthritis
What this study did
NCT00445770 · Pfizer
2006-07 – 2010-07 · Arthritis, Rheumatoid
What this study did
NCT00459706 · Pfizer
2007-09 – 2009-09 · Rheumatoid Arthritis
What this study did
NCT00356590 · Amgen
1998-12 – 2009-04 · Rheumatoid Arthritis
What this study did
NCT00484237 · Wyeth is now a wholly owned subsidiary of Pfizer
2007-04 – 2007-12 · Rheumatoid Arthritis
What this study did
NCT00418717 · Wyeth is now a wholly owned subsidiary of Pfizer
2007-02 – 2007-12 · Arthritis, Rheumatoid
What this study did
NCT00413452 · Amgen
2006-12 – 2007-10 · Rheumatoid Arthritis
What this study did
NCT00443950 · Wyeth is now a wholly owned subsidiary of Pfizer
2006-06 – 2007-07 · Arthritis, Rheumatoid
What this study did
NCT00249041 · Amgen
2005-10 – 2007-03 · Rheumatoid Arthritis
What this study did
NCT00522184 · Centre Hospitalier Universitaire de Nice
2005-02 – 2006-11 · Rheumatoid Arthritis
What this study did
NCT00317538 · Centocor Ortho Biotech Services, L.L.C.
2003-06 – 2004-11 · Rheumatoid Arthritis
What this study did
NCT00078806 · Amgen
2001-06-04 – 2004-05-06 · Juvenile Rheumatoid Arthritis
What this study did
NCT03781375 · Amgen
2000-08-24 – 2002-06-24 · Juvenile Rheumatoid Arthritis
What this study did
NCT00393471 · Wyeth is now a wholly owned subsidiary of Pfizer
2000-10 – 2001-10 · Active Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT03728478 · Istituto Giannina Gaslini
2019-05-29 – 2026-12-31 · Oligoarthritis, Juvenile, Polyarthritis, Juvenile, Rheumatoid Factor Negative
What this study did
NCT07386587 · University of Child Health Sciences and Children's Hospital, Lahore
2026-01-27 – 2026-07-27 · Juvenile Idiopathic Arthritis
What this study did
NCT02987257 · Vanderbilt University Medical Center
2023-03-21 – 2025-10-31 · Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
What this study did
NCT01421069 · Pfizer
2011-10-10 – 2021-02-04 · Juvenile Idiopahtic Arthritis
What this study did
NCT02840175 · Assistance Publique - Hôpitaux de Paris
2017-05-18 – 2020-10-01 · Juvenile Idiopathic Arthritis
What this study did
NCT00468117 · National Institute of Allergy and Infectious Diseases (NIAID)
2007-01 – 2017-07-05 · Type 1 Diabetes Mellitus
What this study did
NCT04345458 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2014-03-06 – 2015-07-20 · Ankylosing Spondylitis
What this study did
Phase 2/3 (10)
Psoriasis
NCT03997786 · Sun Pharmaceutical Industries Limited
2020-01-15 – 2031-08-05 · Moderate-to-severe Chronic Plaque Psoriasis
What this study did
Rheumatoid Arthritis
Other / comorbidity
NCT06011889 · National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
2024-09-04 – 2028-10-18 · SAPHO Syndrome
What this study did
NCT01030120 · University of Utah
2010-12 – 2012-10 · Chronic Idiopathic Urticaria
What this study did
NCT00789997 · Ottawa Hospital Research Institute
2008-11 – 2011-10 · COPD Exacerbation
What this study did
NCT00733096 · Johns Hopkins University
2008-08 – 2011-03 · Lumbosacral Radiculopathy
What this study did
NCT00127387 · The University of Texas Health Science Center at San Antonio
2001-05 – 2005-11 · Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
What this study did
NCT00111956 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2004-04 – 2005-05 · Metabolic Syndrome X
What this study did
NCT00005007 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2000-06 – 2003-03 · Wegener's Granulomatosis
What this study did
NCT00035958 · Children's Hospital Medical Center, Cincinnati
2002-08 – 2002-08 · Dermatomyositis
What this study did
Phase 2 (48)
Psoriasis
NCT01989689 · Emory University
2010-08 – 2013-09 · PSORIASIS
What this study did
NCT00134394 · University of Medicine and Dentistry of New Jersey
2005-02 – 2007-12 · Psoriasis
What this study did
Rheumatoid Arthritis
NCT03193957 · Samsung Bioepis Co., Ltd.
2017-05-15 – 2017-09-25 · Rheumatoid Arthritis
What this study did
NCT00034060 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2002-04 – 2005-12 · Rheumatoid Arthritis, Healthy
What this study did
NCT00001862 · National Eye Institute (NEI)
1999-02 – 2003-03 · Juvenile Rheumatoid Arthritis, Uveitis
What this study did
Other / comorbidity
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT04066348 · Wayne State University
2022-07-01 – 2027-02 · Tinnitus, Noise Induced
What this study did
NCT02464878 · Massachusetts General Hospital
2017-01 – 2022-12 · Kidney Transplant, Type 1 Diabetes
What this study did
NCT02464033 · Johnny Ludvigsson
2015-05 – 2019-02-25 · Diabetes Mellitus, Type 1
What this study did
NCT00841789 · Michael Portman
2009-03 – 2018-08-30 · Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
What this study did
NCT02656082 · University of Leeds
2016-02-01 – 2017-12-31 · Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Chronic Cutaneous
What this study did
NCT00639717 · University of Michigan Rogel Cancer Center
2009-03 – 2016-04 · Graft Versus Host Disease
What this study did
NCT01731457 · Medical University of Warsaw
2011-04 – 2016-02 · Transplanted Kidney Ischemia Reperfusion Injury
What this study did
NCT00789308 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-07-11 – 2014-08-21 · Diabetes Mellitus, Type I
What this study did
NCT01730495 · Haukeland University Hospital
2012-10 – 2014-08 · Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
What this study did
NCT01068353 · University of Southampton
2011-01 – 2013-12 · Alzheimer's Disease
What this study did
NCT00434850 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-10 – 2013-11 · Diabetes Mellitus, Type 1
What this study did
NCT00844142 · Charite University, Berlin, Germany
2005-11 – 2013-07 · Moderate to Severe Active Axial Spondyloarthritis
What this study did
NCT00141739 · University of Michigan Rogel Cancer Center
2004-08 – 2012-09 · Graft-Versus-Host Disease
What this study did
NCT00224874 · National Heart, Lung, and Blood Institute (NHLBI)
2005-09 – 2012-06 · Graft vs Host Disease, Immune System Disorders
What this study did
NCT01289743 · Charite University, Berlin, Germany
2002-02 – 2012-05 · Ankylosing Spondylitis
What this study did
NCT01289730 · Charite University, Berlin, Germany
2002-02 – 2012-05 · Spondyloarthritis
What this study did
NCT00309907 · Children's Oncology Group
2006-04 – 2011-09 · Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Pulmonary Complications, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
What this study did
NCT00797784 · Florida Academic Dermatology Centers
2008-10 – 2011-04 · Discoid Lupus Erythematosus (DLE)
What this study did
NCT00031551 · National Institute of Nursing Research (NINR)
2002-03 – 2010-08 · Stomatitis
What this study did
NCT00293202 · Kaysen, George A., M.D., Ph.D.
2005-01 – 2010-06 · End Stage Renal Disease
What this study did
NCT00285779 · Stanford University
2006-08 – 2009-11 · Lichen Planus
What this study did
NCT00509600 · M.D. Anderson Cancer Center
2004-09 – 2009-04 · Leukemia
What this study did
NCT00447265 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-02 – 2009-03 · Lupus Nephritis
What this study did
NCT00141726 · University of Michigan Rogel Cancer Center
2003-10 – 2009-02 · Lung Injury, Acute, Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans
What this study did
NCT00107991 · University of Pennsylvania
2005-04 – 2008-11 · Hidradenitis Suppurativa
What this study did
NCT00134368 · University of Medicine and Dentistry of New Jersey
2003-11 – 2007-12 · Vitiligo
What this study did
NCT00678782 · University of Padova
2005-04 – 2007-12 · Persistent Knee Joint Synovitis
What this study did
NCT00217386 · Fred Hutchinson Cancer Center
2004-03 – 2007-12 · Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
What this study did
NCT00135720 · Massachusetts General Hospital
2004-06 – 2007-11 · Pemphigus Vulgaris
What this study did
NCT00141713 · University of Michigan Rogel Cancer Center
2003-10 – 2006-12 · Graft-Versus-Host Disease
What this study did
NCT00141791 · Wyeth is now a wholly owned subsidiary of Pfizer
2005-05 – 2006-07 · Asthma
What this study did
NCT00329823 · University of Athens
2005-09 – 2006-05 · Hidradenitis Suppurativa
What this study did
NCT00224393 · The Cleveland Clinic
2001-02 – 2005-08-31 · Primary Systemic Amyloidosis
What this study did
NCT00005853 · Fred Hutchinson Cancer Center
1999-12 – 2005-08 · Leukemia, Myelodysplastic Syndromes
What this study did
NCT00001901 · National Institute of Allergy and Infectious Diseases (NIAID)
1999-02 – 2005-03 · Vasculitis, Wegener's Granulomatosis
What this study did
NCT00063869 · Wyeth is now a wholly owned subsidiary of Pfizer
est. completion 2005-03 · Pulmonary Fibrosis
What this study did
NCT00006070 · National Institute of Dental and Craniofacial Research (NIDCR)
2000-07 – 2004-05 · Healthy, Inflammation
What this study did
NCT00048373 · Baylor College of Medicine
2001-10 – 2004-04 · Histiocytosis, Langerhans-Cell
What this study did
NCT00001955 · National Institute of Dental and Craniofacial Research (NIDCR)
1999-12 – 2004-02 · Temporomandibular Joint Disorder
What this study did
NCT00001954 · National Institute of Dental and Craniofacial Research (NIDCR)
1999-12 – 2003-11 · Sjogren's Syndrome
What this study did
NCT00001893 · National Heart, Lung, and Blood Institute (NHLBI)
1999-08-17 – 2002-12-31 · Asthma
What this study did
Phase 1/2 (13)
Psoriasis
NCT02112097 · ASIS Corporation
2016-01 – 2017-06 · Plaque Psoriasis.
What this study did
NCT00585650 · University of California, Irvine
2007-05 – 2008-05 · Psoriasis
What this study did
Other / comorbidity
NCT03182426 · University of Alberta
2017-08-15 – 2024-07-15 · Diabetes Mellitus, Type 1
What this study did
NCT02821026 · University of Alberta
2016-05 – 2019-11-13 · Type 1 Diabetes
What this study did
NCT00784966 · Virginia Commonwealth University
2011-08 – 2017-09 · Type 1 Diabetes Mellitus
What this study did
NCT00888628 · Massachusetts General Hospital
2009-05 – 2016-08 · Diabetes Mellitus, Type I
What this study did
NCT00201682 · John Byrd
2002-10 – 2009-08 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT00118287 · Fred Hutchinson Cancer Center
2005-04 – 2008-10 · de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
What this study did
NCT00730392 · State University of New York at Buffalo
2002-10 – 2008-01 · Type 1 Diabetes
What this study did
NCT00364572 · Johns Hopkins University
2006-05 – 2007-12 · Sciatica
What this study did
NCT00201838 · Ohio State University Comprehensive Cancer Center
2001-07 – 2007-05 · Pancreatic Neoplasms, Adenocarcinoma
What this study did
NCT00093366 · Fred Hutchinson Cancer Center
2004-06 – 2006-07 · Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
What this study did
NCT00029328 · FDA Office of Orphan Products Development
2001-09 – 2003-09 · Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
What this study did
Phase 1 (32)
Psoriasis
NCT02999776 · Pantec Biosolutions AG
2016-11 – 2018-06 · Psoriatic Plaque
What this study did
Rheumatoid Arthritis
NCT04585711 · Duke University
2026-07-01 – 2027-02-28 · Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Obesity
What this study did
NCT04559412 · Sorrento Therapeutics, Inc.
2021-03-15 – 2024-12 · Rheumatoid Arthritis
What this study did
NCT01294397 · Amgen
2011-03 – 2016-01 · Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
What this study did
NCT00361634 · Amgen
2006-09 – 2010-03 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT03294954 · Baylor College of Medicine
2018-01-18 – 2040-08-10 · Neuroblastoma
What this study did
NCT06585384 · Fondation Ophtalmologique Adolphe de Rothschild
2025-04-15 – 2028-12 · Alzheimer Disease
What this study did
NCT05950724 · Northwestern University
2023-09-17 – 2027-12 · Lung Transplant; Complications
What this study did
NCT04254627 · Nova Southeastern University
2021-09-24 – 2025-09-30 · Gulf War Illness
What this study did
NCT05281614 · Benaroya Research Institute
2022-09-21 – 2024-01-10 · Type 1 Diabetes
What this study did
NCT03792841 · Amgen
2019-02-05 – 2023-06-29 · Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
What this study did
NCT04973566 · Janssen Research & Development, LLC
2021-08-31 – 2022-05-27 · Healthy
What this study did
NCT01865630 · Unity Health Toronto
2021-01 – 2022-01 · Subarachnoid Hemorrhage, Aneurysmal
What this study did
NCT04255498 · South Florida Veterans Affairs Foundation for Research and Education
2017-10-30 – 2020-08-30 · Gulf War Illness, Persian Gulf Syndrome, Occupational Diseases
What this study did
NCT03193203 · Samsung Bioepis Co., Ltd.
2017-03-24 – 2017-08-07 · Healthy
What this study did
NCT03273088 · AryoGen Pharmed Co.
2016-12-04 – 2017-03-15 · Phase 1, Bioequivalence
What this study did
NCT01716637 · Life Extension Foundation Inc.
2010-02 – 2016-05 · Alzheimer's Disease
What this study did
NCT01894412 · Hanwha Chemical
2013-07 – 2015-12 · Healthy
What this study did
NCT00802815 · Washington University School of Medicine
2005-04 – 2014-05 · Inclusion Body Myositis
What this study did
NCT01725620 · LG Life Sciences
2012-11 – 2014-04 · Healthy
What this study did
NCT01865552 · Samsung Bioepis Co., Ltd.
2013-05 – 2013-08 · Healthy
What this study did
NCT01145950 · LG Life Sciences
2010-06 – 2011-01 · Healthy
What this study did
NCT00965666 · Children's Hospital Medical Center, Cincinnati
2005-10 – 2010-10 · Fanconi Anemia
What this study did
NCT00112385 · Brigham and Women's Hospital
2006-03 – 2010-06 · Dermatomyositis
What this study did
NCT00705042 · Wyeth is now a wholly owned subsidiary of Pfizer
2008-07 – 2008-11 · Healthy Subjects
What this study did
NCT00502879 · Wyeth is now a wholly owned subsidiary of Pfizer
2007-07 – 2007-08 · Healthy
What this study did
NCT00203359 · Tobinick, Edward Lewis, M.D.
2004-09 – 2006-04 · Alzheimer's Disease
What this study did
NCT00203320 · Tobinick, Edward Lewis, M.D.
2005-04 – 2006-01 · Alzheimer's Disease
What this study did
NCT00201812 · Ohio State University Comprehensive Cancer Center
2000-11 – 2005-05 · Tumors
What this study did
NCT00091741 · Georgetown University
est. completion 2004-10 · HIV Infection
What this study did
NCT02799498 · Amgen
2003-10 – 2004-01 · Healthy Men and Women
What this study did
Phase 4 (102)
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT02144857 · University of Athens
2014-05-30 – 2023-12-31 · Psoriasis
What this study did
NCT02313922 · Zhejiang University
2014-11 – 2018-08 · Psoriasis
What this study did
NCT02749370 · Amgen
2016-05-18 – 2017-12-06 · Plaque Psoriasis
What this study did
NCT01971346 · University of Michigan
2014-03-13 – 2017-11-01 · Psoriasis
What this study did
NCT02274792 · Amgen
2015-01 – 2015-11 · Plaque Psoriasis
What this study did
NCT01543204 · Amgen
2012-02-01 – 2015-05-29 · Psoriasis
What this study did
NCT00967538 · Innovaderm Research Inc.
2009-09 – 2014-07 · Psoriasis
What this study did
NCT00992394 · Pfizer
2010-01 – 2013-04 · Psoriasis
What this study did
NCT01053819 · University of Alabama at Birmingham
2007-09 – 2012-04 · Psoriasis, Melanoma, Non-melanoma Skin Cancer
What this study did
NCT01132235 · Florida Academic Dermatology Centers
2010-04 – 2010-12 · Psoriasis
What this study did
NCT01237262 · University of Padova
2010-11 – 2010-11 · Moderate to Severe Psoriasis., Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.
What this study did
NCT00640393 · Innovaderm Research Inc.
2008-04 – 2010-03 · Psoriasis Vulgaris
What this study did
NCT00791765 · Amgen
2008-10 – 2010-03 · Psoriasis
What this study did
NCT00332332 · Amgen
2006-03 – 2010-02 · Psoriasis
What this study did
NCT00833729 · Dermatrials Research
2009-02 – 2010-02 · Plaque Psoriasis
What this study did
NCT00663052 · Pfizer
2008-06 – 2010-01 · Plaque Psoriasis, Psoriasis
What this study did
NCT00581555 · Pfizer
2007-10 – 2009-11 · Psoriasis
What this study did
NCT00581100 · Wyeth is now a wholly owned subsidiary of Pfizer
2007-09 – 2009-10 · Nail Psoriasis, Plaque Psoriasis
What this study did
NCT00581165 · Wyeth is now a wholly owned subsidiary of Pfizer
2006-02 – 2007-08 · Psoriasis
What this study did
NCT00195507 · Wyeth is now a wholly owned subsidiary of Pfizer
2004-12 – 2007-02 · Psoriasis
What this study did
NCT00110981 · Amgen
2005-03 – 2006-03 · Psoriasis
What this study did
Psoriatic Arthritis
NCT05135312 · OptiSkin Medical
2021-08-09 – 2022-08-08 · Psoriasis, Psoriatic Arthritis, Psoriatic Nail
What this study did
NCT00111124 · Amgen
— · Psoriasis
What this study did
NCT00127842 · Amgen
2005-08 – 2009-09 · Psoriatic Arthritis
What this study did
NCT00432406 · Chinese University of Hong Kong
2006-05 – 2009-03 · Psoriatic Arthritis
What this study did
NCT00245960 · Wyeth is now a wholly owned subsidiary of Pfizer
2005-12-27 – 2008-03-29 · Psoriatic Arthritis
What this study did
NCT00133315 · Hvidovre University Hospital
2004-09 – 2007-04 · Spondylarthropathies, Ankylosing Spondylitis, Psoriatic Arthritis
What this study did
NCT00161655 · Wyeth is now a wholly owned subsidiary of Pfizer
2005-04 – 2006-12 · Psoriasis, Arthritis, Psoriatic
What this study did
Rheumatoid Arthritis
NCT03976245 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2020-03-01 – 2025-03 · Rheumatoid Arthritis
What this study did
NCT01793519 · Georgetown University
2013-01 – 2024-08-30 · Rheumatoid Arthritis
What this study did
NCT03813771 · University of Leeds
2019-03 – 2023-02 · Rheumatoid Arthritis
What this study did
NCT03649061 · P. Verschueren
2018-06-08 – 2022-07-01 · Arthritis, Rheumatoid
What this study did
NCT02374021 · Brigham and Women's Hospital
2016-07 – 2021-05 · Arthritis, Rheumatoid
What this study did
NCT01602302 · Medical University of Graz
2012-06 – 2020-11-19 · Rheumatoid Arthritis
What this study did
NCT02878161 · Fen Li
2016-01 – 2019-12 · Rheumatoid Arthritis
What this study did
NCT02433184 · University of Leeds
2011-07 – 2019-07 · Rheumatoid Arthritis
What this study did
NCT02353780 · Dr. Larry W. Moreland
2015-03 – 2018-11-30 · Rheumatoid Arthritis (RA)
What this study did
NCT02109289 · Innovaderm Research Inc.
2014-04 – 2016-11 · Rheumatoid Arthritis, Vascular Inflammation
What this study did
NCT01295151 · Julia Brown
2011-08 – 2015-11 · Rheumatoid Arthritis
What this study did
NCT02346877 · Amgen
2015-04 – 2015-10 · Persistence to Enbrel
What this study did
NCT01927757 · Amgen
2013-05-06 – 2015-06-11 · Moderate to Severe Rheumatoid Arthritis
What this study did
NCT01783015 · Pfizer
2013-09 – 2014-08 · Rheumatoid Arthritis
What this study did
NCT02132234 · Jagiellonian University
2013-06 – 2014-07 · Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Hypertension
What this study did
NCT01875991 · Amgen
2013-06-05 – 2014-03-04 · Rheumatoid Arthritis, Plaque Psoriasis
What this study did
NCT00837434 · National Institute of Allergy and Infectious Diseases (NIAID)
2009-03 – 2014-01 · Rheumatoid Arthritis
What this study did
NCT01000441 · University Hospital, Strasbourg, France
2009-12-23 – 2013-08-12 · Rheumatoid Arthritis
What this study did
NCT01313208 · Amgen
2011-03 – 2013-05 · Rheumatoid Arthritis
What this study did
Early phase / not applicable (19)
Psoriasis
NCT02258282 · Chengdu PLA General Hospital
2014-05 – 2022-12 · Psoriasis
What this study did
NCT00477191 · Massachusetts General Hospital
2007-05 – 2013-12 · Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, Hypertension
What this study did
NCT01170715 · Rockefeller University
2010-07-13 – 2013-09-09 · Psoriasis
What this study did
NCT01657513 · University Hospital, Gentofte, Copenhagen
2012-06 – 2013-07 · Psoriasis
What this study did
NCT00550030 · Medical University of Graz
2006-08 – 2010-12 · Psoriasis
What this study did
Rheumatoid Arthritis
NCT00405275 · US Department of Veterans Affairs
2007-07 – 2012-05 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07184853 · First Affiliated Hospital of Zhejiang University
2025-09-25 – 2028-09-25 · Graft vs Host Disease
What this study did
NCT01610947 · University Hospital, Montpellier
2012-05-14 – 2018-10-18 · Spondyloarthritis
What this study did
NCT03033095 · University Hospital, Grenoble
2016-07 – 2018-03-28 · Spondylitis, Ankylosing
What this study did
NCT02722772 · First Affiliated Hospital of Harbin Medical University
2016-02 – 2017-08 · Osteoarthritis of Knee
What this study did
NCT02722811 · First Affiliated Hospital of Harbin Medical University
2016-02 – 2017-08 · Osteoarthritis Of Knee
What this study did
NCT02030613 · Assistance Publique - Hôpitaux de Paris
2013-10-01 – 2017-03-30 · Juvenile Idiopathic Arthritis
What this study did
NCT02031211 · Stanford University
2014-06 – 2016-10 · CRPS, Chronic Regional Pain Syndrome
What this study did
NCT00931957 · Tehran University of Medical Sciences
2010-10 – 2013-10 · Behcet Syndrome, Uveal Disease
What this study did
NCT00825344 · Johns Hopkins University
2009-01 – 2012-08 · Inguinal Hernia, Postoperative Pain
What this study did
NCT00413400 · Massachusetts General Hospital
2006-12 – 2009-09 · Metabolic Syndrome
What this study did
NCT00409318 · Massachusetts General Hospital
2004-04 – 2005-05 · Metabolic Syndrome
What this study did
NCT00276029 · University Hospitals, Leicester
2003-12 – 2004-09 · Asthma
What this study did
NCT00205231 · University of Wisconsin, Madison
2002-05 – 2004-05-01 · HIV Infections
What this study did
Used as active comparator (35)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (22)
Psoriasis
NCT03451851 · Janssen Research & Development, LLC
2018-07-11 – 2026-12-18 · Psoriasis
What this study did
NCT02471144 · Novartis Pharmaceuticals
2015-09-29 – 2023-03-30 · Chronic Severe Plaque-type Psoriasis
What this study did
NCT01646177 · Eli Lilly and Company
2012-07-28 – 2019-07-22 · Psoriasis
What this study did
NCT01597245 · Eli Lilly and Company
2012-05-18 – 2019-06-18 · Psoriasis
What this study did
NCT02346240 · UCB Biopharma S.P.R.L.
2015-02-11 – 2018-12-17 · Psoriasis, Plaque Psoriasis
What this study did
NCT01936688 · Sun Pharmaceutical Industries Limited
2013-09 – 2018-08 · Plaque-type Psoriasis
What this study did
NCT02134210 · Coherus Oncology, Inc.
2014-06-16 – 2016-05-12 · Plaque Psoriasis
What this study did
NCT01891864 · Sandoz
2013-06 – 2015-03 · Chronic Stable Plaque Psoriasis
What this study did
NCT01358578 · Novartis Pharmaceuticals
2011-06 – 2013-07 · Chronic Plaque Psoriasis
What this study did
NCT00710580 · AbbVie (prior sponsor, Abbott)
2008-07 – 2009-04 · Moderate to Severe Plaque Psoriasis
What this study did
NCT00691964 · AbbVie (prior sponsor, Abbott)
2008-05 – 2009-03 · Plaque Psoriasis
What this study did
NCT00454584 · Centocor, Inc.
2007-03 – 2009-01 · Psoriasis
What this study did
Rheumatoid Arthritis
NCT06596772 · mAbxience Research S.L.
2024-10-03 – 2026-02-20 · Rheumatoid Arthritis (RA)
What this study did
NCT04079374 · Joint Stock Company "Farmak"
2018-09-03 – 2023-12-03 · Rheumatoid Arthritis
What this study did
NCT02308163 · Astellas Pharma Inc
2014-08-08 – 2017-11-22 · Rheumatoid Arthritis
What this study did
NCT02357069 · LG Life Sciences
2015-02 – 2016-12 · Arthritis, Rheumatoid
What this study did
NCT02115750 · Coherus Oncology, Inc.
2014-05 – 2016-05 · Rheumatoid Arthritis
What this study did
NCT01895309 · Samsung Bioepis Co., Ltd.
2013-06 – 2015-10 · Rheumatoid Arthritis
What this study did
NCT01394913 · EMS
2013-08 – 2014-06 · Rheumatoid Arthritis
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT02809781 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2016-06 – 2018-12 · Spondylitis, Spondylitis, Ankylosing, Ankylosis, Arthritis, Spondylarthritis, Spondylarthropathies, Spinal Diseases, Musculoskeletal Diseases, Bone Diseases
What this study did
Phase 2 (2)
Rheumatoid Arthritis
NCT00713544 · AstraZeneca
2008-07 – 2009-04 · Rheumatoid Arthritis
What this study did
NCT00520572 · AstraZeneca
2007-08 – 2009-03 · Rheumatoid Arthritis
What this study did
Phase 1 (5)
Psoriasis
NCT01276847 · Merck Sharp & Dohme LLC
2011-03 – 2011-12 · Psoriasis
What this study did
Rheumatoid Arthritis
NCT02481180 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
2015-07-31 – 2017-11-06 · Rheumatoid Arthritis
What this study did
NCT01635686 · Daewoong Pharmaceutical Co. LTD.
2012-09 – 2013-06 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT06392074 · mAbxience Research S.L.
2024-03-07 – 2025-05-12 · Healthy Volunteers
What this study did
NCT01431404 · Hanwha Chemical
2011-08 – 2013-06 · Healthy
What this study did
Phase 4 (5)
Psoriasis
NCT00936065 · Pfizer
2009-07 – 2011-04 · Moderate to Severe Psoriasis
What this study did
Rheumatoid Arthritis
NCT03100253 · Mario Negri Institute for Pharmacological Research
2018-03-01 – 2021-12-31 · Rheumatoid Arthritis
What this study did
NCT02092467 · Pfizer
2014-03-14 – 2020-07-22 · Arthritis, Rheumatoid
What this study did
NCT01331837 · Hoffmann-La Roche
2011-08-02 – 2016-03-25 · Rheumatoid Arthritis
What this study did
NCT01021735 · University of Glasgow
2010-04 – 2015-04 · Rheumatoid Arthritis
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Psoriasis
NCT01001208 · Amgen
2009-11 – 2011-02 · Psoriasis
What this study did
Phase 1/2 (2)
Rheumatoid Arthritis
NCT03160001 · Faiq Gorial
2017-08-15 – 2018-12-10 · Rheumatoid Arthritis (RA)
What this study did
Other / comorbidity
NCT04082910 · Chinese PLA General Hospital
2019-09-15 – 2023-12-30 · Solid Tumor, Hematological Malignancy
What this study did
Phase 4 (1)
Psoriasis
NCT00832364 · Stiefel, a GSK Company
2009-10 – 2010-04 · Plaque Psoriasis
What this study did
Early phase / not applicable (1)
Psoriasis
NCT00800982 · University of California, San Francisco
2008-10 – 2012-03 · Psoriasis
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Psoriasis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Etanercept (Enbrel): this drugApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Weak signal
NCT00111436: Primary endpoint (incidence of adverse events/lab changes) in this 912-patient open-label long-term safety extension (Leonardi et al. 2010, cited by this PMC review), exactly matching this NCT's registered enrollment (912) and design (open-label extension, safety of 50mg QW/BIW etanercept, 48-72 weeks): well tolerated, no significant AE/infection-rate difference between dose groups, no TB/opportunistic infection/demyelination/lymphoma cases.
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00195676: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed)
NCT00237887: REVEAL: PASI 75 response rates of 71% after 16 weeks and 70% after 24 weeks of treatment with adalimumab 40 mg every other week.
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaWeak signalNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Apremilast (Otezla)ApprovedSmall moleculePDE4Reliable signal
NCT03701763: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 (Baseline to Week 16): Apremilast 33.1% vs Placebo 11.5%
NCT03777436: Percentage of Participants With a Modified sPGA-G Response at Week 16 (Baseline and Week 16 of the Placebo-controlled Phase): Placebo-controlled Phase: Apremilast 30 mg 39.6% (95% CI 31.2 to 48) vs Placebo-controlled Phase: Placebo 19.5% (95% CI 12.7 to 26.3)
Betamethasone Dipropionate Emollient Spray (Sernivo)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FReliable signal
NCT03412747: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS) 86.2% vs Adalimumab (RS) 47.2%
NCT03370133: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W (RS) 85% vs Placebo (RS) 4.8% vs Ustekinumab (RS) 49.7%
Brodalumab (Siliq)ApprovedMonoclonal antibodyIL-17 receptor APartial signal
NCT02982005: Coprimary endpoints at week 12: PASI 75 and sPGA success achieved by 92.5% (brodalumab 210mg Q2W) vs 0% (placebo), significantly higher
Calcipotriene / Betamethasone Dipropionate Cream (Wynzora)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptorPartial signal
NCT03802344: Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): MC2-01 Cream -67.5% (Standard Error 20.8) vs Cal/BDP Combination -63.5% (Standard Error 22.2) vs Vehicle -11.7% (Standard Error 21.9)
NCT03308799: PGA treatment success at week 8: 37.4% with CAL/BDP cream (MC2-01) vs 22.8% with CAL/BDP topical suspension (P<0.0001) and 3.7% with vehicle (P<0.0001) (Stein Gold et al., J Drugs Dermatol 2021).
Calcipotriene / Betamethasone Dipropionate Foam (Enstilar)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Calcipotriol / Betamethasone Dipropionate Gel (Taclonex)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaReliable signal
NCT02326298: PASI 75 at Week 16 (CIMPASI-1): certolizumab pegol 200mg Q2W 66.5%, 400mg Q2W 75.8%, placebo 6.5% (P<0.0001 for both doses vs placebo).
NCT02326272: PASI 75 at Week 16 (CIMPASI-2): certolizumab pegol 200mg Q2W 81.4%, 400mg Q2W 82.6%, placebo 11.6% (P<0.0001 for both doses vs placebo).
Desoximetasone (Topicort Spray)ApprovedSmall moleculeGlucocorticoid receptor agonistPartial signal
NCT02618759: Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 ± 2 (28 Days): DSXS1505 10/60 (16.7%) vs Placebo 3/59 (5.1%) missed phase 3 result · pivotal pending
NCT02932462: Clinical Success in Patients With Moderate and Severe Scalp Psoriasis (from baseline to study day 29): DSXS 1535 41/106 (38.7%) vs Placebo 43/126 (34.1%) missed phase 3 result · pivotal pending
Deucravacitinib (Sotyktu)ApprovedSmall moleculeTYK2Reliable signal
NCT04167462: The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5)
NCT03611751: The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1) (Week 16): BMS-986165 253/511 (49.5%) vs Placebo 22/255 (8.6%)
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT02203032: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001.
NCT02207244: Week 16 co-primary endpoints (VOYAGE 2, NCT02207244): IGA 0/1 84.1% guselkumab vs 8.5% placebo (p<0.001); PASI 90 70.0% guselkumab vs 2.4% placebo (p<0.001)
Halobetasol Propionate Foam (Lexette)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptorReliable signal
NCT02742441: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 30.7% vs Vehicle Foam 7.4%
NCT02368210: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 25.3% vs Vehicle Foam 3.9%
Halobetasol Propionate Lotion (Bryhali)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT02514577: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 36.5% vs IDP-122 Vehicle Lotion 8.13%
NCT02515097: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 38.41% vs IDP-122 Vehicle Lotion 11.99%
Halobetasol Propionate / Tazarotene (Duobrii)ApprovedSmall moleculeGlucocorticoid receptor + retinoic acid receptorPartial signal
NCT02462122: Treatment success at week 8 (at least a 2-grade IGA improvement to clear or almost clear), halobetasol propionate 0.01%/tazarotene 0.045% lotion vs vehicle (study 2): 45.3% vs 12.5%, P<.001 (Gold et al., JAAD 2018; CT.gov posted 35.76%/6.98% and 45.33%/12.51%).
NCT02462070: Treatment success at week 8 (at least a 2-grade IGA improvement to clear or almost clear), halobetasol propionate 0.01%/tazarotene 0.045% lotion vs vehicle (study 1): 35.8% vs 7.0%, P<.001 (Gold et al., JAAD 2018; CT.gov posted 35.76%/6.98% and 45.33%/12.51%).
Icotrokinra (Icotyde)ApprovedPeptideIL-23 receptorReliable signal
NCT06095115: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 64.7%
NCT06095102: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 56.7% vs Placebo 5.8%
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT01177800: PASI 75 response at week 10: 81.0% infliximab (5 mg/kg) vs 2.2% placebo (P < 0.001)
NCT00106847: Primary endpoint (PASI 75 at week 10), EXPRESS II trial -- official title fetched directly from the CT.gov API for this NCT matches word-for-word ('...Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Patients With Plaque-Type Psoriasis'): infliximab 3mg/kg 70%, 5mg/kg 75%, vs placebo 2% (P<0.001).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Zymfentra)
Approved(overall)
Monoclonal antibodyTNF-alpha
Reliable signal(overall)
No reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Ixekizumab (Taltz)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo.
NCT01474512: Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA) (Week 12): Ixe Q4W 76.4% | Ixe Q2W 81.8% vs Placebo 3.2%
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT02672852: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001
NCT02684370: PASI90 at Week 16 (UltIMMa-1 trial, NCT02684370): risankizumab 75.3% vs placebo 4.9% vs ustekinumab 42.0% (p<0.0001 vs both comparators)
Roflumilast (Zoryve Foam)ApprovedSmall moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
Roflumilast (Zoryve)ApprovedSmall moleculePDE4Partial signal
NCT04211389: Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Roflumilast Cream 0.3% 99/264 (37.5%) vs Vehicle Cream 9/131 (6.9%)
NCT04211363: Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 (Baseline (Day 1) and Week 8): Rofumilast Cream 0.3% 108/255 (42.4%) vs Vehicle Cream 8/132 (6.1%)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT01358578: Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks): AIN457 150mg 219/327 (67.0%) | AIN457 300mg 249/323 (77.1%) vs Placebo 16/324 (4.9%)
NCT01365455: Percentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks (12 weeks): AIN457 150 mg 71.6% | AIN457 300 mg 81.6% vs Placebo 4.5%
Spesolimab (Spevigo)ApprovedMonoclonal antibodyIL-36 receptorReliable signal
NCT03782792: Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1 (At Week 1.): Spesolimab 900 mg i.v SD 54.3% (95% CI 38.2% to 69.5%) vs Placebo 5.6% (95% CI 1% to 25.8%)
TapinarofApprovedSmall moleculeAryl hydrocarbon receptor, Aryl Hydrocarbon Receptor AgonistReliable signal
NCT03956355: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation (Baseline to Week 12): Tapinarof (DMVT-505) 35.4% (Standard Error 2.75) vs Vehicle Cream 6% (Standard Error 2.08)
NCT03983980: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation (Baseline to Week 12): Tapinarof (DMVT-505) Cream Group 40.2% (Standard Error 2.82) vs Vehicle Cream Group 6.3% (Standard Error 1.99)
Tildrakizumab (Ilumya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT01722331: Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)): Tildrakizumab 200 mg (Part 1) 62.3% | Tildrakizumab 100 mg (Part 1) 63.8% vs Placebo (Part 1) 5.8%
NCT01729754: Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1) (Week 12): Tildrakizumab 200 mg 65.6% | Tildrakizumab 100 mg 61.2% vs Placebo 5.8% | Etanercept 50 mg 48.2%
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT00307437: PASI 75 at Week 12 (intent-to-treat, PHOENIX 2 trial): placebo 15/410 vs ustekinumab 45 mg 273/409 vs ustekinumab 90 mg 311/411; p<0.001 for each dose vs placebo.
NCT00267969: PASI 75 at week 12: ustekinumab 45mg 67.1% vs placebo 3.1% (difference 63.9%, 95% CI 57.8-70.1, p<0.0001); ustekinumab 90mg 66.4% vs placebo 3.1% (difference 63.3%, 95% CI 57.1-69.4, p<0.0001).
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40Reliable signalFeatured results are non-efficacy only in this race
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Amdokitug (Yisaituo)Phase 3Monoclonal antibodyIL-17Anot yet gradedNo reviewed efficacy summary in this indication
Dimethyl Fumarate (Skilarence)Phase 3Small moleculeNrf2 pathway (fumaric acid ester)not yet gradedNo reviewed efficacy summary in this indication
EbdarokimabPhase 3Monoclonal antibodyIL-12/23 p40not yet gradedNo reviewed efficacy summary in this indication
EnvudeucitinibPhase 3Small moleculeTYK2Reliable signal
NCT06586112: PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all)
NCT06588738: ONWARD2, week 16 co-primary endpoints vs placebo (intention-to-treat, nonresponder imputation): PASI 75 70.4% with envudeucitinib 40 mg twice daily (n=433) vs 13.7% with placebo (n=211); sPGA 0/1 57.3% vs 5.7%; both P < 0.0001 (Cochran-Mantel-Haenszel). PASI 90: 53.1% vs 4.3%. Apremilast 30 mg twice daily (n=215): PASI 75 38.6%, sPGA 0/1 27.4% (Alumis AAD 2026 late-breaking presentation).
FadeucravacitinibPhase 3Small moleculeTYK2Partial signal
NCT06109818: PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved
GumokimabPhase 3Monoclonal antibodyIL-17APartial signal
NCT06066125: PASI 75 response at Week 12: 94.6% with gumokimab; PASI 100: 47.7%
HB0017Phase 3Monoclonal antibodyIL-17APartial signal
NCT05531682: Co-primaries PASI 90 and sPGA 0/1 at week 12: HB0017 300 mg (n=41) vs placebo (n=40), PASI 90 69.4% vs 1.0% and sPGA 0/1 78.2% vs 1.1%, both P<0.001. The registry lists three HB0017 dosing regimens and 160 participants; the abstract reports one regimen in 81 patients and gives no result for the other two regimens.
HS-10374Phase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
HS-20137Phase 3Monoclonal antibodyIL-23 p19not yet gradedNo reviewed efficacy summary in this indication
ImsidolimabPhase 3Monoclonal antibodyIL-36 receptorPartial signalFeatured results are non-efficacy only in this race
JNJ-78934804
Phase 3(overall)
CombinationIL-23 p19, TNF-alpha
not yet graded(overall)
No reviewed efficacy summary in this indication
LecankitugPhase 3Monoclonal antibodyIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
MufemilastPhase 3Small moleculePDE4Partial signal
NCT04839328: PASI75 比例分别为 53.6% vs 16.0%,sPGA 0/1 率分别为 31.3% vs 6.4% (PASI75 at week 16: Hemay005 53.6% vs placebo 16.0%; sPGA 0/1: 31.3% vs 6.4%)
NetakimabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT03390101: • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment (week 12): BCD-085 Q2W 66/85 (77.6%) | BCD-085 Q4W 70/84 (83.3%) vs Placebo 0/44 (0.0%)
Nomelcitinib (D-2570)Phase 3Small moleculeTYK2Partial signal
NCT06278350: Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001)
PicankibartPhase 3Monoclonal antibodyIL-23 p19Reliable signal
NCT06049810: PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons
NCT05645627: Co-primary 1, PASI 90 at week 16: 80.3% picankibart 200 mg vs 2.0% placebo (p<0.0001), met. Co-primary 2, sPGA 0/1 at week 16: 93.5% vs 13.1% (p<0.0001), met. Response rates from the JAAD paper; p-values from the Innovent release, as the paper abstract does not print them.
PiclidenosonPhase 3Small moleculeAdenosine A3 receptorPartial signal
NCT03168256: PASI 75 at week 16: 9.7% (3mg) vs 2.6% (placebo), p=0.037; linear improvement through week 32 (PASI 75: 19.6%)
NCT01265667: PASI 75 at week 12: CF101 2 mg 8.5% vs placebo 6.9%, P=0.621, tested at a 0.035 significance level (J Drugs Dermatol 2016). missed
PonesimodPhase 3Small moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
Prifemilast (HPP737)Phase 3Small moleculePDE4Partial signal
NCT07712731: Co-primary endpoints at week 16, prifemilast 20 mg once daily vs apremilast 30 mg twice daily: PASI 75 64.6% vs 35.3% and sPGA 0/1 55.6% vs 31.3% (both P<0.0001) (2026-10-09).
NCT07712705: The placebo-controlled Phase 3 was positive per the sponsor, with responses kept through 52 weeks; figures were not given (2026-10-09).
QL2106Phase 3Monoclonal antibodyIL-23 p19not yet gradedNo reviewed efficacy summary in this indication
RoconkibartPhase 3Monoclonal antibodyIL-17AReliable signal
NCT05975268: Both co-primary endpoints and key secondary endpoints showed statistically significant and clinically meaningful improvements
RSS0393Phase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
SYHX1901Phase 3Small moleculeJAK/SYKPartial signal
NCT05858047: Per CSPC: positive Phase 2 results in moderate to severe plaque psoriasis, with all dose groups showing a therapeutic effect. The company gives no PASI 75 figures or statistics in text.
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
TQH3906Phase 3Small moleculeTYK2Partial signal
NCT06542614: At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks
VunakizumabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT04839016: Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025).
NCT03463187: PASI 75 at week 12: 56.8% (40 mg), 65.8% (80 mg), 81.6% (160 mg), and 86.5% (240 mg) vs 5.4% placebo; P < .001 for all
WD-890Phase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ZasocitinibPhase 3Small moleculeTYK2Reliable signal
NCT06973291: LATITUDE Atlas, PASI 100 at week 16: more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), more than 2.5 times the response rate for deucravacitinib.
NCT06088043: Co-primary 1, sPGA 0/1 at week 16: 71.4% zasocitinib vs 10.7% placebo (p<0.001), met. Co-primary 2, PASI 75 at week 16 vs placebo: superiority shown per Takeda's topline release (response rates and p not printed in Takeda's releases), met. Ranked secondary, PASI 90 at week 16: 61.3% vs 5.0% placebo and 16.8% apremilast (p<0.001).
CMS-D001Phase 2/3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
HB0034Phase 2/3Monoclonal antibodyIL-36 receptornot yet gradedNo reviewed efficacy summary in this indication
SFA-002Phase 2/3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
SonelokimabPhase 2Antibody-derived scaffoldIL-17A/FReliable signal
NCT03384745: Primary endpoint, IGA 0/1 at week 12: placebo 0.0%, sonelokimab 30mg 48.1% (p<0.0001), 60mg 84.6% (p<0.0001), 120mg normal load 77.4% (p<0.0001), 120mg augmented load 88.2% (p<0.0001), secukinumab 300mg (active reference) 77.4% (p<0.0001) vs placebo.
Hemay007
Phase 1(overall)
Small moleculeTNF-alpha
Partial signal(overall)
No reviewed efficacy summary in this indication
LPX-TI641Phase 1Small moleculeTIM receptor (Treg-expanding)not yet gradedNo reviewed efficacy summary in this indication
S-4321Phase 1Multispecific antibodyPD-1 / FcγRIIb (dual)not yet gradedNo reviewed efficacy summary in this indication
SOR102
Phase 1(overall)
Biologic (subtype unspecified)TNF-alpha, IL-23 p19
Weak signal(overall)
No reviewed efficacy summary in this indication
Girocitinib
—(overall)
Small moleculeTYK2/JAK1Partial signalNo reviewed efficacy summary in this indication
BalinatunfibDiscontinuedSmall moleculeTNF-alphaWeak signal
NCT06073119: Percentage of Participants With a 75% or Greater Psoriasis Area and Severity Index (PASI) Score Reduction From Baseline (PASI75) at Week 12 (Baseline (Day 1) and Week 12): SAR441566 200 mg BID 44% | SAR441566 100 mg BID 50% | SAR441566 200 mg QD 58.3% | SAR441566 100 mg QD 28% | SAR441566 50 mg QD 33.3% vs Placebo 20%

Large race: only the 86 furthest-along competitors are listed; 37 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Enbrel (etanercept) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1Lung Transplant; ComplicationsEnrolling by invitation
Est. primary completion 2026-12 · NCT05950724 · CT.gov ↗
What to watch
Phase 2Tinnitus, Noise InducedActive not recruiting
Est. primary completion 2026-12 · NCT04066348 · CT.gov ↗
What to watch
2027 (3)
March 2027 (1)
Phase 4Spondyloarthritis (SpA), Ankylosing Spondylitis (AS)Recruiting
Est. primary completion 2027-03-01 · NCT06707194 · CT.gov ↗
What to watch
September 2027 (1)
Early phase / not applicableGraft vs Host DiseaseRecruiting
Est. primary completion 2027-09-25 · NCT07184853 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1NeuroblastomaActive not recruiting
Est. primary completion 2027-12 · NCT03294954 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1Alzheimer DiseaseRecruiting
Est. primary completion 2028-06 · NCT06585384 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2/3SAPHO SyndromeRecruiting
Est. primary completion 2028-10-18 · NCT06011889 · CT.gov ↗
What to watch
2029 (1)
November 2029 (1)
Phase 4Juvenile Idiopathic Arthritis (JIA)Not yet recruiting
Est. primary completion 2029-11-11 · NCT07904780 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch

See the full readout calendar ↗